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Abstract
Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most impor-
tant chapter of nanomedicine. Nanobiotechnology has refined and extended the limits of molecular diagnosis of
cancer, for example, through the use of gold nanoparticles and quantum dots. Nanobiotechnology has also
improved the discovery of cancer biomarkers, one such example being the sensitive detection of multiple protein
biomarkers by nanobiosensors. Magnetic nanoparticles can capture circulating tumor cells in the bloodstream fol-
lowed by rapid photoacoustic detection. Nanoparticles enable targeted drug delivery in cancer that increases effi-
cacy and decreases adverse effects through reducing the dosage of anticancer drugs administered. Nanoparticulate
anticancer drugs can cross some of the biological barriers and achieve therapeutic concentrations in tumor and
spare the surrounding normal tissues from toxic effects. Nanoparticle constructs facilitate the delivery of various
forms of energy for noninvasive thermal destruction of surgically inaccessible malignant tumors. Nanoparticle-
based optical imaging of tumors as well as contrast agents to enhance detection of tumors by magnetic reso-
nance imaging can be combined with delivery of therapeutic agents for cancer. Monoclonal antibody nanoparticle
complexes are under investigation for diagnosis as well as targeted delivery of cancer therapy. Nanoparticle-based
chemotherapeutic agents are already on the market, and several are in clinical trials. Personalization of cancer
therapies is based on a better understanding of the disease at the molecular level, which is facilitated by nanobio-
technology. Nanobiotechnology will facilitate the combination of diagnostics with therapeutics, which is an impor-
tant feature of a personalized medicine approach to cancer.
Introduction
Nanotechnology is the creation and utilization of mate-
rials, devices and systems through the control of matter
on the nanometer-length scale, that is, at the level of
atoms, molecules and supramolecular structures. Given
the inherent nanoscale functional components of living
cells, it was inevitable that nanotechnology would be
applied in biotechnology settings, giving rise to the term
nanobiotechnology, that is, the application of nanotech-
nology in the life sciences. Nanobiotechnology is already
starting to show the promise of an impact on health
care. Nanomedicine is defined as the application of
nanobiotechnology to medicine and is based on the use
of nanoscale materials and devices for diagnosis and
drug delivery as well as for the development of
advanced pharmaceuticals referred to as nanopharma-
ceuticals [1]. Nanobiotechnology is also being applied to
refine surgery from microsurgery to nanosurgery. Exam-
ples include the construction of nanoscale robots,
nanobots, for navigating the human body to detect as
well as treat various diseases, and cell surgery using
nanodevices and nanolasers. During the past few years,
considerable progress has been made in the application
of nanobiotechnology in cancer, that is, nanooncology,
which is currently the most important chapter of
nanomedicine.
Nanobiotechnology plays an important role in the dis-
covery of biomarkers of cancer. Several drugs in devel-
opment for cancer are based on nanobiotechnology, and
a few of these are already approved. Nanobiotechnol-
ogy-based devices are in development as aids to cancer
surgery. Finally, nanobiotechnology is playing an impor-
tant role in personalized therapy for cancer. The impact
of nanobiotechnology on oncology is shown schemati-
cally in Figure 1.
Role of nanotechnology in cancer diagnostics
Nanobiotechnologies have extended the limits of
and refined molecular diagnostics [2]. Nanobiotech-
nology offers a novel set of tools for the detection of
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follows:
1. It can complement existing technologies and
make significant contributions to cancer detection,
prevention, diagnosis and treatment.
2. It would be extremely useful in the area of bio-
marker research and provide additional sensitivity in
assays with relatively small sample volumes.
3. Examples of applications of nanobiotechnology in
cancer diagnostics include quantum dots (QDs) and
the use of nanoparticles for tumor imaging.
Gold nanoparticles for cancer diagnosis
By attaching monoclonal antibodies (mAbs), which can
recognize a specific cancer cell, to gold nanoparticles or
nanorods the “heating phenomenon” can be used in can-
cer detection. This acoustic signal gives valuable informa-
tion about the presence of cancer cells. Gold nanoparticles
conjugated to anti-epidermal growth factor receptor (anti-
EGFR) mAbs specifically and homogeneously bind to the
surface of the cancer cells with 600% greater affinity than
to the noncancerous cells. This specific and homogeneous
binding is found to give a relatively sharper surface plasma
resonance (SPR) absorption band with a red shifted maxi-
mum compared to that observed when added to the non-
cancerous cells [3]. The particles that worked the best in
the El-Sayed et al. [3] study were 35 nm in size. These
results suggest that SPR scattering imaging or SPR absorp-
tion spectroscopy generated from antibody conjugated
gold nanoparticles may be useful in molecular biosensor
techniques for the diagnosis and investigation of oral
epithelial cancer cells in vivo and in vitro. Advantages of
using this technique include:
1. Gold nanoparticles are not toxic to human cells.
A similar technique with QDs uses semiconductor
crystals to mark cancer cells, but the semiconductor
material is potentially toxic to the cells and humans.
2. It does not require expensive high-powered
microscopes or lasers to view the results. All it takes
is a simple, inexpensive microscope and white light.
3. The results are instantaneous. If a cancerous tis-
sue is sprayed with gold nanoparticles containing the
antibody, the results can be seen immediately. The
scattering is so strong that a single particle can be
detected [3].
Quantum dots for molecular diagnosis of cancer
There is considerable interest in the use of QDs as inor-
ganic fluorophores, owing to the fact that they offer sig-
nificant advantages over conventionally used fluorescent
markers. For example, QDs have fairly broad excitation
spectra, from ultraviolet to red, that can be tuned,
depending on their size and composition.
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Figure 1 Role of nanobiotechnology in the management of cancer. This is a schematic of the role of nanobiotechnology and its interaction
with various other technologies and approaches used in the management of cancer. (Reproduced by permission of Jain PharmaBiotech.)
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oxide nanoparticles can be combined to create a single
nanoparticle probe that can yield clinically useful images
of both tumors and the molecules involved in cancer
[4]. In magnetic resonance imaging (MRI) experiments,
this combination nanoparticle generated an MRI signal
that was over threefold more intense than the same
number of iron oxide nanoparticles. These dual-mode
nanoparticles were labeled with an antibody that binds
to polysialic acid molecules, which are found on the sur-
face of certain lung tumors. These targeted nanoparti-
cles were quickly taken up by cultured tumor cells and
were readily visible using fluorescence microscopy.
DNA methylation contributes to carcinogenesis by silen-
cing key tumor suppressor genes. An ultrasensitive and
reliable nanotechnology assay, MS-qFRET (fluorescence
resonance energy transfer), can detect and quantify DNA
methylation [5]. In this method, bisulfite-modified DNA is
subjected to polymerase chain reaction (PCR) amplifica-
tion with primers that would differentiate between methy-
lated and unmethylated DNA. QDs bind to methylated
DNA strands, which then light up and are identifiable via
a spectrophotometer. A MS-qFRET test of blood samples
can be used for noninvasive cancer screening. It can also
be used to determine whether a cancer treatment is effec-
tive and thus enable personalized chemotherapy.
Nanotechnology for detection of cancer biomarkers
Any specific molecular alteration of a cell on the DNA,
RNA, metabolite or protein level may be referred to as a
molecular biomarker. From a practical point of view, the
biomarker would specifically and sensitively reflect a dis-
ease state and could be used for diagnosis as well as for
disease monitoring during and following therapy [6].
Currently available molecular diagnostic technologies
have been used to detect biomarkers of various diseases
such as cancer. Nanotechnology has further refined the
detection of biomarkers. The physicochemical character-
istics and high surface areas of nanoparticles make them
ideal candidates for developing platforms for harvesting
biomarkers. Some biomarkers also form the basis of
innovative molecular diagnostic tests.
A magnetic nanosensor technology is up to 1,000 times
more sensitive than any technology now in clinical use,
can detect biomarker proteins over a range of concentra-
tions three times broader than any existing method and
is accurate regardless of which bodily fluid is being ana-
lyzed [7]. The nanosensor chip also can search for up to
64 different proteins simultaneously and has been shown
to be effective in early detection of tumors in mice, sug-
gesting that it may open the door to significantly earlier
detection of even the most elusive cancers in humans.
The magnetic nanosensor can successfully detect cancers
in mice when levels of cancer-associated proteins are still
well below concentrations detectable using the current
standard method, the enzyme-linked immunosorbent
assay. The sensor also can be used to detect biomarkers
of diseases other than cancer.
Investigating the potential for capturing circulating
tumor cells
A method has been described for magnetically capturing
circulating tumor cells in the bloodstream of mice fol-
lowed by rapid photoacoustic detection [8]. Magnetic
nanoparticles, which were functionalized to target a
receptor commonly found in breast cancer cells, bound
and captured circulating tumor cells under a magnet.
To improve detection sensitivity and specificity, gold-
plated carbon nanotubes conjugated with folic acid were
used as a second contrast agent for photoacoustic ima-
ging. Through integrating in vivo multiplex targeting,
magnetic enrichment, signal amplification and multico-
lor recognition, this approach enables circulating tumor
cells to be concentrated from a large volume of blood in
the vessels of tumor-bearing mice and has potential
applications for the early diagnosis of cancer and the
prevention of metastasis in humans.
Imaging applications of nanobiotechnology in cancer
Highly lymphotropic superparamagnetic iron oxide nano-
particles (SPIONs), measuring 2 to 3 nm on average
(Combidex, Advanced Magnetics, Cambridge, Mass,
USA), gain access to lymph nodes by means of interstitial
lymphatic fluid transport. SPIONs have been used in con-
junction with high-resolution MRI to reveal small and
otherwise undetectable lymph node metastases. In patients
with prostate cancer who undergo surgical lymph node
resection or biopsy, MRI with lymphotropic SPIONs can
identify all patients with nodal metastases. This is impor-
tant for the management of cancer, but is not possible
with conventional MRI alone. Occult lymph node metas-
tases in patients with prostate cancer have been identified
by this technique prior to salvage radiation therapy [9].
QDs are attractive as optical imaging agents owing to
their high brightness and photo- and biostability. Biolu-
minescence resonance energy transfer QDs can improve
the signal-to-background ratio for real-time imaging lar-
gely by suppressing background signal [10].
Nanotechnology-based drugs for cancer
Approximately 150 drugs in development for cancer are
based on nanotechnology. Some of these are already
approved, as shown in Table 1, and the rest are in var-
ious stages of development.
Current clinical trials using nanobiotechnology for cancer
Clinical trial phases of anticancer drugs based on
nanobiotechnology are shown in Table 2. Not all of
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yet, but those that are available are described in the
following text.
CPX-1
CPX-1 is a novel liposome-encapsulated formulation of
irinotecan and floxuridine designed to prolong in vitro
optimized synergistic molar ratios of both drugs follow-
ing infusion. An open-label, single-arm, dose-escalating
phase I study was conducted to determine the maxi-
mum tolerated dose and pharmacokinetics of CPX-1 in
patients with advanced solid tumors [11]. The results
showed that CPX-1 was well tolerated, and antitumor
activity was shown in patients with advanced solid
tumors.
MCC-465
MCC-465 is an immunoliposome-encapsulated doxoru-
bicin (DOX). The liposome is tagged with polyethylene
glycol (PEG) and the F(ab”)2 fragment of human mAb
GAH (goat anti-human), which positively reacts to >90%
of cancerous stomach tissues but negatively to all
normal tissues. In preclinical studies, MCC-465 showed
superior cytotoxic activity against several human
stomach cancer cells compared with DOX or DOX-
incorporated PEG liposomes. A phase I clinical trial was
conducted to define the maximum tolerated dose, dose-
limiting toxicity, recommended phase II dose and phar-
macokinetics of MCC-465 [12]. The results showed
that MCC-465 was well tolerated, and the recommended
dose for a phase II study was considered to be
32.5 mg/m
2 in an equivalent amount of DOX. A phase
II trial was recommended, but further information is
currently not available.
NC-6004
Polymeric micelles are expected to increase the accumu-
lation of drugs in tumor tissues utilizing the EPR
(enhanced permeability and retention) effect and to
incorporate various kinds of drugs into the inner core
by chemical conjugation or physical entrapment with
relatively high stability. The size of the micelles can be
controlled within the diameter range of 20-100 nm to
ensure that the micelles do not pass through normal
vessel walls; therefore, a reduced incidence of the side
effects of the drugs may be expected as a result of the
decreased volume of distribution. There are several
anticancer agent-incorporated micelle carrier systems
under clinical evaluation. Phase I studies of a CDDP
(cisplatin) -incorporated micelle, NC-6004, and a phase
II study of a PTX (Paclitaxel) -incorporated micelle,
NK105 for stomach cancer, are in progress [13].
PK1 doxorubicin
Phase I studies of polymer doxorubicin (PK1) showed
signs of activity coupled with fivefold decreased anthra-
cycline toxicity in chemotherapy-refractory patients.
Phase II studies were conducted using a similar material
in patients with breast cancer, non-small cell lung can-
cer and colorectal cancer [14]. The results showed effi-
cacy with limited side effects, supporting the concept
that polymer-bound drugs can improved anticancer
activity. PK1 is now in phase III clinical trials.
Table 1 Approved anticancer drugs using nanocarriers
a
Trade name/compound Manufacturer Nanocarrier
Abraxane/paclitaxel Abraxis Biosciences Albumin-bound paclitaxel
Bexxar/anti-CD20 conjugated to iodine-131 Corixa/GlaxoSmithKline Radioimmunoconjugate
DaunoXome/daunorubicin Diatos (available in France) Liposome
Doxil/Caelyx/doxorubicin Ortho Biotech Liposome
Myoset/doxorubicin Cephalon (available in Europe) Nonpegylated liposome
Oncaspar/PEG-L-asparaginase Enzon Polymer-protein conjugate
Ontak/IL-2 fused to diphtheria toxin Eisai Inc Immunotoxic fusion protein
SMANCS/zinostatin Yamanouchi Pharma Polymer-protein conjugate
Zevalin/anti-CD20 conjugated to yttrium-90 Cell Therapeutics Inc. Radioimmunoconjugate
Zoladex/goserelin acetate AstraZeneca Polymer rods
aPEG, polyethylene glycol; IL-2, interleukin-2; SMANCS, styrene maleic anhydride neocarzinostatin. Reproduced by permission
© Jain PharmaBiotech.
Table 2 Clinical trials of anticancer drugs using
nanocarriers
a
Compound Nanocarrier Trial stage
CPX-1 irinotecan Liposome Phase I [11]
LE-SN38 irinotecan Liposome Phase II colorectal cancer
MCC465 doxorubicin mAb-liposome Phase I [12]
NC-6004 cisplatin Micelle Phase II [13]
NK105 paclitaxel Micelle Phase II
NK911 doxorubicin Micelle Phase I
PK1 doxorubicin HPMA copolymer Phase II/III [14]
SP1049C doxorubicin Micelle Phase III [15]
amAb, monoclonal antibody; HPMA, N-(2-hydroxypropyl)methacrylamide.
Reproduced by permission
© Jain PharmaBiotech. References to clinical trials
are given in section “Current clinical trials using nanobiotechnology for
cancer” of the main article.
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The antitumor activity of SP1049C, a novel P-glycoprotein
targeting micellar formulation of doxorubicin consisting of
DOX and two nonionic block copolymers, has been evalu-
ated in patients with advanced adenocarcinomas of the
esophagus and gastroesophageal junction [15]. SP1049C
had a notable single-agent activity in patients with adeno-
carcinomas of the esophagus and gastroesophageal junc-
tion, as well as an acceptable safety profile. These results,
in addition to the results of preclinical studies, demon-
strate superior antitumor activity of SP1049C compared
with DOX in a standard formulation. Phase III clinical
trials are now in progress.
Role of nanobiotechnology in therapeutic delivery
for cancer
Nanoparticle formulations help to overcome the issue of
drug solubility, which is an essential factor for drug
effectiveness. Another advantage is facilitation of drug
delivery across various barriers, the most important of
which is the blood-brain barrier, which limits access to
brain tumors. Other major advantages include targeted
drug delivery, use of lower doses with reduced toxicity
and facilitation of a combination of diagnostics with
therapeutics for cancer. Several nanobiotechnologies,
mostly based on nanoparticles, have been used to facili-
tate drug delivery in cancer, and a classification is
shown in Table 3.
Nanoparticle formulations of anticancer drugs
An example of nanoparticle formulations of anticancer
drugs is paclitaxel, which is widely used to treat multiple
types of solid tumors. The commercially available pacli-
taxel formulation uses Cremophor/ethanol (C/E) as the
solubilizer. A study evaluated the effects of nanoparticle
formulation of paclitaxel on its tissue distribution in
experimental animals [16]. The nanoparticle and C/E for-
mulations showed significant differences in paclitaxel dis-
position: The nanoparticles yielded 40% smaller area
under the blood concentration-time curve and faster
blood clearance of total paclitaxel concentrations (sum of
free, protein-bound and nanoparticle-entrapped drug).
The tissue specificity of the two formulations was differ-
ent. The nanoparticles showed longer retention and higher
accumulation in organs and tissues. Solid tumors have
unique features, such as leaky tumor blood vessels and
defective lymphatic drainage, that promote the delivery
and retention of particles, a phenomenon recognized as
the enhanced permeability and retention effect. Nanofor-
mulation can more easily enter and accumulate within
tumor cells. This means that higher doses of the drug can
be delivered, increasing its anticancer effects while
decreasing the side effects associated with systematic che-
motherapy. However, there are many variable factors, such
as clearance of nanoparticles in the circulation by the kid-
neys and trapping by reticuloendothelial cells, that affect
the amount of anticancer nanoparticles retained in the
tumor. One way to overcome some of these variables is
targeted drug delivery.
Gold nanoparticles (2 nm) have been covalently functio-
nalized with paclitaxel [17]. The organic shell of hybrid
nanoparticles contains 67% by weight of paclitaxel, which
corresponds to ~70 molecules of the drug per 1 nanoparti-
cle. This approach provides an opportunity to prepare
hybrid particles with a well-defined amount of drug and
offers a new alternative for the design of nanosize drug-
delivery systems. Follow-up studies will determine the
potency of the paclitaxel-loaded nanoparticles. Since each
ball is loaded with a uniform number of drug molecules, it
will be relatively easy to compare the effectiveness of the
nanoparticles with the effectiveness of generally adminis-
tered paclitaxel. This technique could help to deliver more
of the drug directly to the cancer cells and reduce the side
effects of chemotherapy. The aim is to improve the effec-
tiveness of the drug by increasing its ability to stay bound
to microtubules within the cell.
The best known of the approved drugs is nanoparticle
albumin-bound paclitaxel (Abraxis Biosciences’/Celgene,
Summit, NJ, USA) Abraxane, which is based on proprie-
tary Protosphere nanoparticle technology, also referred
to as nanoparticle albumin-bound or nab™ technology.
This technology integrates biocompatible proteins with
drugs to create the nanoparticle form of the drug having
a size of about 100-200 nm. SPARC (secreted protein
acidic and rich in cysteine), a protein overexpressed and
secreted by cancer cells, binds albumin to concentrate
albumin-bound cytotoxic drugs at the tumor. The solvent
Cremophor-EL, used previously in formulations of pacli-
taxel, causes severe hypersensitivity reactions. Because
Abraxane is solvent-free, solvent-related toxicities are
eliminated and administration can occur more rapidly.
Abraxane also has a different toxicity profile than sol-
vent-based paclitaxel, including a lower rate of severe
neutropenia. A pivotal randomized, controlled phase III
clinical trial compared the safety and efficacy of
260 mg/m
2 of Abraxane to 175 mg/m
2 of Taxol adminis-
tered every 3 weeks in patients with metastatic breast
cancer [18]. Abraxane was found to be superior to Taxol
with regard to lesion response rate as well as tumor pro-
gression rate. It was approved for the treatment of meta-
static breast cancer and is being evaluated in non-small
cell lung cancer, ovarian cancer, melanoma and cervical
cancer.
Targeted drug delivery using nanobiotechnology
Principles of targeted drug delivery
The basic principle of targeted drug delivery in cancer
using nanoparticles injected intravenously into the blood
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receptors on the cancer cell, anchor themselves to it and
diffuse inside the cell. Once inside, the nanoparticle dis-
integrates, causing a nearly instantaneous release of the
drug precisely where it is needed. Nanoparticles can be
chemically programmed to have an affinity for the cell
wall of tumors or attached to mAb ligands that bind
specifically to receptors on tumor cells. To be effective,
the particles must evade the body’s immune system,
penetrate into the cancer cells and discharge the drugs
before being recognized by the cancer cells.
Nanosystems are emerging that may be very useful for
tumor-targeted drug delivery. Novel nanoparticles are
preprogrammed to alter their structure and properties
during the drug delivery process to make them most
effective for delivery [19]. This alteration can be
achieved through the incorporation of molecular sensors
that are able to respond to physical or biological stimuli,
including changes in pH, redox potential or enzymes.
Nanoparticles are suitable for two specific tasks
required for targeted drug delivery to pathological sites
in the body: (1) passive enhanced permeability and
retention based on the longevity of the pharmaceutical
carrier in the blood, leading to its accumulation in
pathological sites with compromised vasculature, and
(2) active targeting based on the attachment of specific
ligands to the surface of pharmaceutical carriers to
recognize and bind pathological cells [20]. Differentially
expressed molecules at receptors can be used as docking
sites to concentrate drug conjugates and nanoparticles
at tumor sites [21].
Targeted delivery of biological therapies for cancer
Physical forces (for example, electric or magnetic fields,
ultrasound, hyperthermia or light) may contribute to
focusing and triggered activation of nanosystems. Biolo-
gical drugs delivered with programmed nanosystems
also include plasmid DNA, small interfering RNA
(siRNA) and other therapeutic nucleic acids.
A tumor-targeted nanodrug consisting of SPIONs
(MN-EPPT-siBIRC5), which is designed to specifically
carry siRNA to human breast tumors, binds the tumor-
specific antigen uMUC-1 found on over 90% of human
breast adenocarcinomas, translating into a significant
decrease in tumor growth rate [22]. Following intrave-
nous injection, the nanodrug demonstrates a preferential
Table 3 Classification of nanobiotechnology approaches to drug delivery in cancer
a
Approach Examples
Nanoparticles Nanoparticle formulations of anticancer drugs, for example, paclitaxel
Exosomes for cancer drug delivery Dexosomes (exosomes produced by dendritic cells) as cancer vaccines
Nanoencapsulation and enclosure of anticancer drugs Enclosing drugs in lipid nanocapsules
Encapsulating drugs in hydrogel nanoparticles
Micelles for drug delivery in cancer
Targeted delivery of anticancer therapy Targeted drug delivery with nanoparticles
Pegylated nanoliposomal formulation
Folate-linked nanoparticles
Carbon magnetic nanoparticles for targeted drug delivery
Nanoparticle-aptamer bioconjugates
Nanodroplets for site-specific cancer treatment
Lipid-based nanocarriers
Targeted antiangiogenic therapy using nanoparticles
Nanoparticles for delivery of drugs to brain tumors
Combination of nanoparticles with radiotherapy Combination with boron neutron capture therapy
Nanoengineered silicon for brachytherapy
Combination with physical modalities of cancer therapy Combination with laser ablation of tumors
Combination with photodynamic therapy
Combination with thermal ablation
Combination with ultrasound
Nanoparticle-mediated gene therapy p53 gene therapy of cancer
Immunolipoplex for delivery of p53 gene
Intravenous delivery of FUS1 gene
Combination of diagnostics and therapeutics Nanoshells as adjuncts to thermal tumor ablation
Perfluorocarbon nanoparticles
Nanocomposite devices
aFrom Jain KK: The Handbook of Nanomedicine, Totowa, NJ: Humana/Springer; 2008 (reproduced by permission).
© Jain PharmaBiotech.
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near-infrared (NIR) optical imaging. This approach
enables simultaneous targeted delivery of siRNA to
tumors and the imaging of the delivery process.
Cyclosert system for targeted delivery of anticancer
therapeutics
Cyclosert™ (Calando Pharmaceuticals, Pasadena, CA,
USA) is the first nanoparticle drug transport platform to
be designed de novo and synthesized specifically to over-
come limitations in existing technologies used for the
systemic transport of therapeutics to targeted sites
within the body. Based on small cyclic repeating mole-
cules of glucose called cyclodextrins, Cyclosert promotes
the ability of cytotoxic drugs to inhibit the growth of
human cancer cells while reducing toxicity and remain-
ing nonimmunogenic cells at therapeutic doses. In parti-
cular, the system is designed to reduce the toxicity of
the drugs until they actually reach the targeted tumor
cells, where the active drug is released in a controlled
fashion. Animal studies have shown that the Cyclosert
system can safely deliver tubulysin A, a potent but
highly toxic antitumor agent. In vitro studies have
shown the tubulysin-Cyclosert conjugate to be effective
against multiple human cancer cell lines. The conjugate
is stable and 100 times more water-soluble than the free
drug. Calando (Pasadena, CA, USA) is developing
CALAA01, a siRNA, for anticancer therapy using Cyclo-
sert as a delivery system.
IT-101 (Calando) is a de novo designed experimental
therapeutic composed of linear, cyclodextrin (CD)-
containing polymer conjugates of camptothecin (CPT)
that assemble into 40-nm-diameter nanoparticles via
polymer-polymer interactions that involve inclusion
complex formation between the CPT and the CD. Parti-
cle size, near-neutral surface charge and CPT release
rate were specifically designed into IT-101. The Cyclo-
sert platform forms nanoscale constructs with hydrody-
namic diameters between 30 and 60 nm. This makes
Cyclosert-based drugs ideal for effective delivery to solid
tumors. Preclinical animal studies have shown extended
circulation times, tumor accumulation, slow release of
the CPT and anticancer efficacy that directly correlate
to the properties of the nanoparticle. Release of CPT
can disassemble the nanoparticle into individual polymer
chains ~10 nm in size that are capable of renal clear-
ance. IT-101 has been evaluated in patients with
relapsed or refractory cancer following two cycles of
therapy by intravenous infusion. Interim analysis has
shown that IT-101 is well tolerated and that pancytope-
nia is the dose-limiting toxicity [23]. Pharmacokinetic
data were favorable and consistent with results from
preclinical animal studies. In the patients studied, IT-
101 showed longer half-life, lower clearance and lower
volume of distribution than that seen in patients treated
with other camptothecin-based drugs. IT-101 is in phase
II clinical trials.
Ultrasonic tumor imaging and targeted chemotherapy
by nanobubbles
Drug delivery in polymeric micelles combined with
tumor irradiation by ultrasound results in effective drug
targeting, but this technique requires prior tumor ima-
ging. A new targeted drug delivery method for doxoru-
bicin used ultrasound to image tumors while also
releasing the drug from nanobubbles into the tumor
implants in mice [24]. At physiologic temperatures,
nanodroplets converted into nanobubbles. Doxorubicin
was localized in the nanobubble walls formed by the
block copolymer. Upon intravenous injection into mice,
DOX-loaded micelles and nanobubbles extravasated
selectively into the tumor interstitium, where the nano-
bubbles coalesced to produce microbubbles. When
exposed to ultrasound, the bubbles generated echoes,
w h i c hm a d ei tp o s s i b l et oi m a g et h et u m o r .T h es o u n d
energy from the ultrasound popped the bubbles, releas-
ing DOX, which enhanced intracellular uptake by tumor
cells in vitro to a statistically significant extent compared
to that observed with nanobubbles that were not
exposed to ultrasound.
In summary, multifunctional nanoparticles that are
tumor-targeted drug carriers, long-lasting ultrasound
contrast agents and enhancers of ultrasound-mediated
drug delivery have been developed and deserve further
exploration as cancer therapeutics.
Nanoparticle-based thermal ablation of cancer
Several forms of energy have been used for the destruc-
tion of tumor cells that cannot be reached for conven-
tional surgical excision. Thermal ablation therapy is the
most promising of these methods but is limited by
incomplete tumor destruction and damage to adjacent
normal tissues. Current radiofrequency ablation techni-
ques require invasive needle placement and are limited
by accuracy of targeting. Use of nanoparticles has refined
noninvasive thermal ablation of tumors, and several
nanomaterials have been used for this purpose. These
include gold nanomaterials, iron nanoparticles, magnetic
nanoparticles, carbon nanotubes and affisomes. Heating
of the particles can be induced by magnets, lasers, ultra-
sound, photodynamic therapy and low-power X-rays [1].
In addition to delivering heat, hyperthermia offers
additional treatment options by enhancing the effects of
chemoradiation treatments. A lower radiation dose is
required to kill the same fraction of cells when they are
also subjected to hyperthermia. This is because hypoxic
cells are resistant to radiation, but heat destroys hypoxic
cells as efficiently as normal cells [1].
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Noninvasive radiowave thermal ablation of cancer cells
is feasible when facilitated by gold nanoparticles [25].
CYT-6091, a pegylated colloidal gold nanoparticle con-
taining tumor necrosis factor-a bound to its surface, has
been extensively investigated as an adjuvant and has
been shown to enhance thermal therapies [26]. This
technique could be adapted to in vivo use.
Photothermal therapy can be used to heat gold nano-
particles to destroy the tumor, while another option
would be to include gold particles in capsules filled with
cancer medication. The capsule attaches to the cancer
cell and is heated, and the medicine is released locally.
Plasmon-resonant gold nanorods, which have large
absorption cross sections at NIR frequencies, are very
effective as multifunctional agents for image-guided can-
cer therapies based on localized hyperthermia. Nanorods
coated with cetyltrimethylammonium bromide (a catio-
nic surfactant used in nanorod synthesis) are interna-
lized quickly into cancer cells by a nonspecific uptake
pathway, whereas the removal of cetyltrimethylammo-
nium bromide from nanorods functionalized with folate
results in their accumulation on the cell surface over
the same time interval [27]. Thus the nanorods render
the tumor cells highly susceptible to photothermal
damage when irradiated at the nanorods’ longitudinal
plasmon resonance.
Gold nanoshell-based, targeted, multimodal contrast
agents in NIR are fabricated and utilized as a diagnostic
and therapeutic probe for MRI, fluorescence optical
imaging and photothermal cancer therapy of breast car-
cinoma cells in vitro [28]. This may enable diagnosis as
well as treatment of cancer during one hospital visit.
Magnetic nanoparticles for thermal ablation of tumors
Magnetic thermal ablation has been examined under
in vivo animal conditions. Magnetic nanoparticles are
promising tools for minimally invasive elimination of
small tumors in the breast using magnetically induced
heating. The approach complies with the increasing
demand for breast-conserving therapies and has the
advantage of offering a selective and refined tuning of
the degree of energy deposition, allowing an adequate
temperature control at the target [29].
Anti-human epidermal growth factor receptor 2 (anti-
HER2) antibody can induce antitumor responses and
can be used in delivering drugs to HER2-overexpressing
cancer. Anti-HER2 immunoliposomes containing mag-
netite nanoparticles, which act as tumor-targeting vehi-
cles, have been used to combine anti-HER2 antibody
therapy with hyperthermia [30]. When introduced into
SKBr3 breast cancer cells in vitro, 60% of magnetite
nanoparticles incorporated into the SKBr3 cells. The
cells were then heated at 42.5°C under an alternating
magnetic field, resulting in strong cytotoxic effects.
These results suggest that this novel therapeutic tool is
applicable to the treatment of HER2-overexpressing
cancer.
Magnetorelaxometry can also be used to monitor the
accumulation of magnetic nanoparticles before cancer
therapy, with magnetic heating being an important pre-
condition for treatment success [31]. Although nanopar-
ticle-mediated thermal therapy is a promising treatment
of cancers, challenges posed by this form of hyperther-
mia include the nontarget biodistribution of nanoparti-
cles in the reticuloendothelial system when administered
systemically, the inability to visualize or quantify the
global concentration and spatial distribution of these
particles within tumors, the lack of standardized thermal
modeling as well as algorithms for determining dose,
and the concerns regarding their biocompatibility [32].
Laser-induced thermal destruction of cancer using
nanoparticles
Single-walled carbon nanotubes (SWCNTs) show strong
optical absorbance 700- to 1,100-nm NIR laser impulses.
SWCNTs emit heat when they absorb energy from NIR
light. Tissue is relatively transparent to NIR, which sug-
gests that targeting SWCNTs to tumor cells, followed
by noninvasive exposure to NIR light, will ablate tumors
within the range of NIR. One study has demonstrated
the specific binding of mAb-coupled SWCNTs to tumor
cells in vitro, followed by their highly specific ablation
with NIR light [33]. Only the specifically targeted cells
were killed after exposure to NIR light. Selective cancer
cell destruction can be achieved by functionalization of
SWCNTs with a folate moiety, selective internalization
of carbon nanotubes inside cells labeled with folate
receptor tumor biomarkers, and NIR-triggered cell
death, without harming receptor-free normal cells.
Photodynamic therapy of cancer using nanoparticles
Poly(lactic-co-glycolic acid) nanoparticles can encapsu-
late the photosensitizer mesotetraphenylporpholactol
and are not phototoxic upon systemic administration,
but upon cellular internalization the photosensitizer is
released from the nanoparticle and becomes highly
phototoxic. In vivo experiments have shown complete
eradication of cancers by photodynamic therapy (PDT)
in mouse models.
A nanocarrier consisting of polymeric micelles of diacyl-
phospholipid-poly(ethylene glycol) (PE-PEG) coloaded
with the photosensitizer drug 2-[1-hexyloxyethyl]-2-
devinyl pyropheophorbide and magnetic Fe3O4 nanoparti-
cles have been used for guided drug delivery, together
with light-activated PDT, for cancer [34]. The magneto-
phoretic control on the cellular uptake provides enhanced
imaging and phototoxicity. These multifunctional
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nanochemistry for targeting PDT.
In a novel nanoformulation for PDT of cancer, the
photosensitizer molecules are covalently incorporated
into organically modified silica nanoparticles [35]. These
incorporated photosensitizer molecules retain their spec-
troscopic and functional properties and can robustly
generate cytotoxic singlet oxygen molecules upon
photoirradiation. The advantage offered by this cova-
lently linked nanofabrication is that the drug is not
released during systemic circulation, which is often a
problem with physical encapsulation. These nanoparti-
cles are also avidly taken up by tumor cells and demon-
strate phototoxic action, thereby improving the
diagnosis as well as PDT of cancer, the efficacy of which
remains controversial for some types of cancer.
Targeted delivery of thermosensitive affibody-conjugated
liposomes for cancer
Thermosensitive liposomes have been used as vehicles
for the delivery and release of drugs to tumors. To
improve the targeting efficacy for breast cancer treat-
ment, a HER2-specific affibody molecule was conjugated
to the surface of thermosensitive small unilamellar lipo-
somes measuring 80-100 nm, referred to as “Affisomes,”
to study the effects of this modification on physical
characteristics and the stability of the resulting prepara-
tion [36]. Affisomes released calcein, a water-soluble
fluorescent probe, in a temperature-dependent manner,
with optimal leakage (90%-100%) at 410°C. Affisomes
are therefore promising candidates for targeted thermo-
therapy of breast cancer.
Role of nanotechnology in personalized therapy of cancer
Personalized medicine simply means the prescription of
specific therapeutics best suited for an individual. The
scope of personalized medicine is much broader than
that indicated by the term genomic medicine.P e r s o n a -
lized management is usually based on pharmacogenetic,
pharmacogenomic, pharmacoproteomic and pharmaco-
metabolic information, but other individual variations in
patients and environmental factors are also taken into
consideration [37]. In cancer cases, the variation in
behavior of cancer of the same histological type from
one patient to another is also taken into consideration.
Personalization of cancer therapies is based on a better
understanding of the disease at the molecular level, and
nanotechnology will play an important role in this area
[38]. With so many nanotechnologies available for drug
delivery, it is recommended that computational mathe-
matical tools be used to predict which nanovectors,
surface modifications, therapeutic agents and penetra-
tion enhancers to use for a multistage drug-delivery
strategy that would enable efficient localized delivery of
chemotherapeutic drugs and lead to significant improve-
ments in therapy efficacy as well as reduced systemic
toxicity [39]. Such an approach can be optimized for
personalized oncology.
Combination of diagnostics with therapeutics
The refinement of molecular diagnostics and the inte-
gration of diagnosis with therapy are important features
of personalized medicine. As described in the sections
on diagnosis and targeted drug delivery, use of the same
nanoparticle for diagnosis as well as therapy enables
integration of two important facets of cancer manage-
ment. Dendrimers can be used as advanced contrast
agents for imaging techniques such as MRI and can be
targeted specifically to cancer cells. Dendrimers can also
be used to deliver a variety of cancer therapies to
improve their safety and efficacy. For example, applica-
tions of dendrimers in photodynamic therapy, boron
neutron capture therapy and gene therapy for cancer
are being investigated [40].
A biocompatible, multimodal iron oxide nanoparticle
has been synthesized for targeted cancer therapy and for
optical imaging as well as MRI. A modified solvent dif-
fusion method is used for the coencapsulation of both
an anticancer drug and NIR dyes [41]. The resulting
folate-derived nanoparticles combining diagnostic and
therapeutic properties can be used for imaging as well
as targeted killing of folate-expressing cancer cells.
Concluding remarks
The rationale for using nanobiotechnology in oncology is
that nanoparticles have optical, magnetic or structural
properties that are not available from larger molecules or
bulk solids. When linked with tumor-targeting ligands
such as mAbs, peptides or small molecules, these nano-
particles can be used to target tumor antigens (biomar-
kers) as well as tumor vasculatures with high affinity and
specificity [42]. Nanoparticles measuring 5-100 nm in
diameter have sufficiently large surface areas and func-
tional groups for conjugating to multiple diagnostic and
therapeutic anticancer agents. Recent advances have led
to bioaffinity nanoparticle probes for molecular and cel-
lular imaging, targeted nanoparticle drugs for cancer
therapy and integrated nanodevices for early cancer
detection and screening. Nanobiotechnology has contrib-
uted significantly to the diagnosis and therapy of cancer
and, by enabling a combination of these, will facilitate the
development of personalized management of cancer.
Nanobiotechnology has facilitated the discovery of bio-
markers that can be used to diagnose and treat cancer
based on the molecular profiles of individual patients.
Nanoparticles enable targeted delivery of cancer thera-
peutics and increase efficacy as well as reduce adverse
effects.
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widespread use of nanobiotechnology in clinical oncol-
ogy. There is some concern about the toxicity of nano-
particles, and extensive investigations are in progress to
resolve this issue. There is no consensus on the real
risks of nanomaterials. Risk evaluation presents chal-
lenges because of a lack of data, the complexity of nano-
materials, measurement difficulties and undeveloped
hazard assessment frameworks. This topic is discussed
in detail in a chapter of a special report on nanobiotech-
nology [43]. Detailed discussion is beyond the scope of
this article, but some of the conclusions of this review
are listed below:
1. The risk of nanoparticles depends on their type;
some are toxic, whereas others have negligible toxi-
city and some even have a tissue-protective effect.
2. Measures are available to reduce the toxicity of
nanoparticles.
3. The use of biodegradable polymer nanoparticles is
suitable for drug delivery as there is no significant
toxicity.
Nanooncology has a promising future, and further
advances are anticipated in the next 5 years. It is feasible
to use molecular tools to design a miniature robotic
device, a nanobot, that can be introduced in the body to
locate and identify cancer cells and finally destroy them.
The device would have a biosensor to identify cancer
cells and a supply of anticancer substance that could be
released on encountering cancer cells. A small computer
could be incorporated to program and integrate the com-
bination of diagnosis and therapy and provide the possi-
bility of monitoring the in vivo activities by an external
device. Since there is no universal anticancer agent, the
computer program could match the type of cancer to the
most appropriate agent. Such a device could be
implanted as a prophylactic measure in people who do
not show any obvious manifestations of cancer. It would
circulate freely and could detect and treat cancer at the
earliest stage. Such a device could be reprogrammed
through removal control and enable a change of strategy
if the lesion encountered is other than cancer [44].
Abbreviations
ELISA: enzyme-linked immunosorbent assay; mAb: monoclonal antibody;
MRI: magnetic resonance imaging; MS: mass spectrometry; NIR: near-infrared;
PCR: polymerase chain reaction; PDT: photodynamic therapy; QD: quantum
dots; SPR: surface plasma resonance; SWCNT: single wall carbon nanotube.
Author’s information
KKJ, a retired professor of neurosurgery, has been involved in biotechnology
for several years with a focus on translation into clinical medicine and
integration of technologies to develop personalized medicine. KKJ is the
author of 425 publications, including 17 books and 49 special reports on
biopharmaceutical topics, including nanobiotechnology. His publications
include articles in several scientific journal as well as book chapters on
nanobiotechnology and nanomedicine. A book on the role of
nanobiotechnology in molecular diagnostics was published in 2006 and
Handbook of Nanomedicine in 2008 by Humana/Springer Biosciences.
Editorial board membership includes the journals Nanomedicine, Technology
in Cancer Research & Treatment, and Journal of Nanoneuroscience.H ei sa n
invited lecturer on nanobiotechnology as well as a member of review/
advisory panels for research grants by various government agencies in the
United States (U.S. Army), Canada, the European Union, the Netherlands and
Singapore.
Competing interests
The authors declare that they have no competing interests.
Received: 19 August 2010 Accepted: 13 December 2010
Published: 13 December 2010
References
1. Jain KK: A Handbook of Nanomedicine Totowa, NJ: Humana/Springer; 2008.
2. Jain KK: Applications of nanobiotechnology in clinical diagnostics. Clin
Chem 2007, 53:2002-2009.
3. El-Sayed IH, Huang X, El-Sayed M: Selective laser photo-thermal therapy
of epithelial carcinoma using anti-EGFR antibody conjugated gold
nanoparticles. Cancer Lett 2006, 239:129-135.
4. Choi JS, Jun YW, Yeon SI, Kim HC, Shin JS, Cheon J: Biocompatible
heterostructured nanoparticles for multimodal biological detection. JA m
Chem Soc 2006, 128:15982-15983.
5. Bailey VJ, Easwaran H, Zhang Y, Griffiths E, Belinsky SA, Herman JG,
Baylin SB, Carraway HE, Wang TH: MS-qFRET: a quantum dot-based
method for analysis of DNA methylation. Genome Res 2009, 19:1455-1461.
6. Jain KK: A Handbook of Biomarkers New York: Springer; 2010.
7. Gaster RS, Hall DA, Nielsen CH, Osterfeld SJ, Yu H, Mach KE, Wilson RJ,
Murmann B, Liao JC, Gambhir SS, Wang SX: Matrix-insensitive protein
assays push the limits of biosensors in medicine. Nat Med 2009,
15:1327-1332.
8. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP: In vivo
magnetic enrichment and multiplex photoacoustic detection of
circulating tumour cells. Nat Nanotechnol 2009, 4:855-860.
9. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS,
Islam T, Guimaraes AR, Weissleder R, Harisinghani M: Lymphotropic
nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies
occult lymph node metastases in prostate cancer patients prior to
salvage radiation therapy. Clin Imaging 2009, 33:301-305.
10. Kosaka N, McCann TE, Mitsunaga M, Choyke PL, Kobayashi H: Real-time
optical imaging using quantum dot and related nanocrystals.
Nanomedicine (Lond) 2010, 5:765-776.
11. Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE,
Janoff AS, Louie AC: Safety, pharmacokinetics, and efficacy of CPX-1
liposome injection in patients with advanced solid tumors. Clin Cancer
Res 2009, 15:692-700.
12. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M,
Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A,
Takamatsu Y, Ito K, Takahashi K: Phase I and pharmacokinetic study of
MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in
patients with metastatic stomach cancer. Ann Oncol 2004, 15:517-525.
13. Matsumura Y: Poly (amino acid) micelle nanocarriers in preclinical and
clinical studies. Adv Drug Deliv Rev 2008, 60:899-914.
14. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C,
Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D,
Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J: Phase II
studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of
breast, lung and colorectal cancer. Int J Oncol 2009, 34:1629-1636.
15. Valle JW, Armstrong A, Newman C, Alakhov V, Pietrzynski G, Brewer J,
Campbell S, Corrie P, Rowinsky EK, Ranson M: A phase 2 study of
SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients
with advanced adenocarcinoma of the esophagus and
gastroesophageal junction. Invest New Drugs 2010.
16. Yeh TK, Lu Z, Wientjes MG, Au JL: Formulating paclitaxel in nanoparticles
alters its disposition. Pharm Res 2005, 22:867-874.
17. Gibson JD, Khanal B, Zubarev E: Paclitaxel-functionalized gold
nanoparticles. J Am Chem Soc 2007, 129:11653-11661.
Jain BMC Medicine 2010, 8:83
http://www.biomedcentral.com/1741-7015/8/83
Page 10 of 1118. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M,
O’Shaughnessy J: Superior efficacy of albumin-bound paclitaxel, ABI-007,
compared with polyethylated castor oil-based paclitaxel in women with
metastatic breast cancer: results of a phase III trial. J Clin Oncol 2005,
23:7794-7803.
19. Wagner E: Programmed drug delivery: nanosystems for tumor targeting.
Expert Opin Biol Ther 2007, 7:587-593.
20. Torchilin VP: Passive and active drug targeting: drug delivery to tumors
as an example. Handb Exp Pharmacol 2010, 197:3-53.
21. Ruoslahti E, Bhatia SN, Sailor MJ: Targeting of drugs and nanoparticles to
tumors. J Cell Biol 2010, 188:759-768.
22. Kumar M, Yigit M, Dai G, Moore A, Medarova Z: Image-guided breast
tumor therapy using a siRNA nanodrug. Cancer Res 2010, 70:7553-7561.
23. Yen Y, Synold T, Schluep T, Hwang J, Oliver J, Davis ME: First-in-human
phase I trial of a cyclodextrin-containing polymer-camptothecin
nanoparticle in patients with solid tumors. J Clin Oncol 2007,
25(18S):14078.
24. Rapoport N, Gao Z, Kennedy A: Multifunctional nanoparticles for
combining ultrasonic tumor imaging and targeted chemotherapy. J Natl
Cancer Inst 2007, 99:1095-1106.
25. Cardinal J, Klune JR, Chory E, Jeyabalan G, Kanzius JS, Nalesnik M, Geller DA:
Noninvasive radiofrequency ablation of cancer targeted by gold
nanoparticles. Surgery 2008, 144:125-132.
26. Shenoi MM, Anderson J, Bischof JC: Nanoparticle enhanced thermal
therapies. Conf Proc IEEE Eng Med Biol Soc 2009 2009, 1979-1982.
27. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng JX, Wei A: Hyperthermic
effects of gold nanorods on tumor cells. Nanomedicine (Lond) 2007,
2:125-132.
28. Bardhan R, Chen W, Perez-Torres C, Bartels M, Huschka RM, Zhao LL,
Morosan E, Pautler RG, Joshi A, Halas NJ: Nanoshells with targeted
simultaneous enhancement of magnetic and optical imaging and
photothermal therapeutic response. Adv Functional Mater 19:3901-3909.
29. Hilger I, Hergt R, Kaiser WA: Use of magnetic nanoparticle heating in the
treatment of breast cancer. IEE Proc Nanobiotechnol 2005, 152:33-39.
30. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T:
Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for
combination of antibody therapy with hyperthermia. Cancer Lett 2004,
212:167-175.
31. Richter H, Kettering M, Wiekhorst F, Steinhoff U, Hilger I, Trahms L:
Magnetorelaxometry for localization and quantification of magnetic
nanoparticles for thermal ablation studies. Phys Med Biol 2010, 55:623-633.
32. Krishnan S, Diagaradjane P, Cho SH: Nanoparticle-mediated thermal
therapy: evolving strategies for prostate cancer therapy. Int J
Hyperthermia 2010, 26:775-789.
33. Chakravarty P, Marches R, Zimmerman NS, Swafford AD, Bajaj P,
Musselman IH, Pantano P, Draper RK, Vitetta ES: Thermal ablation of tumor
cells with antibody-functionalized single-walled carbon nanotubes. Proc
Natl Acad Sci USA 2008, 105:8697-8702.
34. Cinteza LO, Ohulchanskyy TY, Sahoo Y, Bergey EJ, Pandey RK, Prasad PN:
Diacyllipid micelle-based nanocarrier for magnetically guided delivery of
drugs in photodynamic therapy. Mol Pharm 2006, 3:415-423.
35. Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, Pandey RK,
Oseroff AR, Prasad PN: Organically modified silica nanoparticles with
covalently incorporated photosensitizer for photodynamic therapy of
cancer. Nano Lett 2007, 7:2835-2842.
36. Puri A, Kramer-Marek G, Campbell-Massa R, Yavlovich A, Tele SC, Lee SB,
Clogston JD, Patri AK, Blumenthal R, Capala J: HER2-specific affibody-
conjugated thermosensitive liposomes (Affisomes) for improved delivery
of anticancer agents. J Liposome Res 2008, 18:293-307.
37. Jain KK: Textbook of Personalized Medicine New York: Springer; 2009.
38. Jain KK: Role of nanobiotechnology in developing personalized medicine
for cancer. Technol Cancer Res Treat 2005, 4:407-416.
39. Sakamoto J, Annapragada A, Decuzzi P, Ferrari M: Antibiological barrier
nanovector technology for cancer applications. Expert Opin Drug Deliv
2007, 4:359-369.
40. Baker JR Jr: Dendrimer-based nanoparticles for cancer therapy.
Hematology Am Soc Hematol Educ Program 2009, 708-719.
41. Santra S, Kaittanis C, Grimm J, Perez JM: Drug/dye-loaded, multifunctional
iron oxide nanoparticles for combined targeted cancer therapy and dual
optical/magnetic resonance imaging. Small 2009, 5:1862-1868.
42. Nie S, Xing Y, Kim GJ, Simons JW: Nanotechnology applications in cancer.
Annu Rev Biomed Eng 2007, 9:257-288.
43. Jain KK: Nanobiotechnology: Technologies, Markets and Companies Basel,
Switzerland: Jain PharmaBiotech Publications; 2010.
44. Jain KK: Recent advances in nanooncology. Technol Cancer Res Treat 2008,
7:1-13.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/8/83/prepub
doi:10.1186/1741-7015-8-83
Cite this article as: Jain: Advances in the field of nanooncology. BMC
Medicine 2010 8:83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jain BMC Medicine 2010, 8:83
http://www.biomedcentral.com/1741-7015/8/83
Page 11 of 11